The article "Gasdermins: a dual role in pyroptosis and tumor immunity" by Yang and Jiang explores the multifaceted role of gasdermin (GSDM) proteins in pyroptosis and their implications for tumor immunity. GSDM proteins, including GSDMA/B/C/D, GSDME (DFNA5), and DFNB59, play a crucial role in puncturing cell membranes, releasing immune factors, and inducing cell death. These proteins are activated by caspases and granzymes through inflammasome signaling pathways, contributing to immune defense against pathogens and cancers. Pyroptosis, characterized by inflammation, is facilitated by GSDM proteins, leading to the release of inflammatory molecules and cell death. In the context of tumor immunity, pyroptosis has both tumor-promoting and tumor-inhibiting effects. While moderate pyroptosis can inhibit tumor growth, excessive levels may promote tumor progression. The article discusses the signaling pathways of GSDM-mediated pyroptosis, including the canonical and non-canonical inflammasome pathways, and the role of various inflammatory factors such as IL-1β and IL-18. It also reviews the expression and clinical significance of GSDM proteins in different tumors, highlighting their potential as therapeutic targets in cancer treatment. The authors emphasize the need for further research to optimize the therapeutic potential of pyroptosis induction in cancer treatment while addressing challenges related to specificity, immune responses, and clinical applicability.The article "Gasdermins: a dual role in pyroptosis and tumor immunity" by Yang and Jiang explores the multifaceted role of gasdermin (GSDM) proteins in pyroptosis and their implications for tumor immunity. GSDM proteins, including GSDMA/B/C/D, GSDME (DFNA5), and DFNB59, play a crucial role in puncturing cell membranes, releasing immune factors, and inducing cell death. These proteins are activated by caspases and granzymes through inflammasome signaling pathways, contributing to immune defense against pathogens and cancers. Pyroptosis, characterized by inflammation, is facilitated by GSDM proteins, leading to the release of inflammatory molecules and cell death. In the context of tumor immunity, pyroptosis has both tumor-promoting and tumor-inhibiting effects. While moderate pyroptosis can inhibit tumor growth, excessive levels may promote tumor progression. The article discusses the signaling pathways of GSDM-mediated pyroptosis, including the canonical and non-canonical inflammasome pathways, and the role of various inflammatory factors such as IL-1β and IL-18. It also reviews the expression and clinical significance of GSDM proteins in different tumors, highlighting their potential as therapeutic targets in cancer treatment. The authors emphasize the need for further research to optimize the therapeutic potential of pyroptosis induction in cancer treatment while addressing challenges related to specificity, immune responses, and clinical applicability.